이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

이전에 치료받지 않은 국소 진행성 절제불가능 또는 전이성 PD-L1 선별 비소세포폐암 환자를 대상으로 티라골루맙과 아테졸리주맙 병용을 위약과 아테졸리주맙과 비교한 연구 (SKYSCRAPER-01)

2026년 11월 6일 업데이트: Hoffmann-La Roche

이전에 치료받지 않은 국소 진행성 절제불가능 또는 전이성 PD-L1 선별 비환자를 대상으로 아테졸리주맙과 위약 병용을 비교한 항 Tigit 항체인 티라골루맙과 아테졸리주맙 병용의 III상, 무작위, 이중 맹검, 위약 대조 연구 -소세포폐암

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

연구 개요

연구 유형

중재적

등록 (실제)

620

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 185 47
        • Metropolitan Hospital
      • Athens, 그리스, 104 31
        • Sotiria Hospital
      • Larissa, 그리스, 411 10
        • University Hospital of Larissa
      • Thessaloniki, 그리스, 570 01
        • Diavalkaniko Hospital
      • 's-Hertogenbosch, 네덜란드, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Ede, 네덜란드, 6716 RP
        • Ziekenhuis Gelderse Vallei
      • Leeuwarden, 네덜란드, 8934 AD
        • Frisius MC Leeuwarden
      • The Hague, 네덜란드, 2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Guishan Dist., 대만, 33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Kaohsiung City, 대만, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City, 대만, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, 대만, 23561
        • Taipei Medical University ?Shuang Ho Hospital
      • Taichung, 대만, 407
        • Taichung Veterans General Hospital
      • Tainan, 대만, 704
        • National Cheng Kung Uni Hospital
      • Taipei, 대만, 112
        • Taipei Veterans General Hospital
      • Zhongzheng Dist., 대만, 10048
        • National Taiwan University Hospital
      • Cheongju-si, 대한민국, 28644
        • Chungbuk National University Hospital
      • Gyeonggi-do, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Gyeonggi-do, 대한민국, 16499
        • Ajou University Medical Center
      • Incheon, 대한민국, 21565
        • Gachon University Gil Medical Center
      • Jeollanam-do, 대한민국, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, 대한민국, 08308
        • Korea University Guro Hospital
      • Seoul, 대한민국, 6351
        • Samsung Medical Center
      • Seoul, 대한민국, 03181
        • Kangbuk Samsung Medical Center
      • Suwon, 대한민국, 442-723
        • St. Vincent's Hospital
      • Frankfurt, 독일, 60488
        • Krankenhaus Nordwest
      • Großhansdorf, 독일, 22927
        • LungenClinic Großhansdorf GmbH
      • Halle, 독일, 06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
      • Immenhausen, 독일, 34376
        • Fachklinik für Lungenerkrankungen
      • Löwenstein, 독일, 74245
        • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
      • Münster, 독일, 48153
        • Gemeinschaftspraxis für Hämatologie und Onkologie
      • Stuttgart, 독일, 70376
        • Klinik Schillerhöhe
    • Moscow Oblast
      • Moscow, Moscow Oblast, 러시아 제국, 143422
        • MEDSI Clinical Hospital on Pyatnitsky Highway
      • Moscow, Moscow Oblast, 러시아 제국, 105229
        • Main Military Clinical Hospital named after N.N. Burdenko
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 189646
        • Institute of Oncology
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197089
        • St. Petersburg Med Univ
      • Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197758
        • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
    • Mexico CITY (federal District)
      • México, Mexico CITY (federal District), 멕시코, 06100
        • Cryptex Investigacion Clinica SA de CV
    • Nuevo León
      • Monterrey, Nuevo León, 멕시코, 64710
        • AVIX Investigación Clínica S.C
    • Querétaro
      • Querétaro City, Querétaro, 멕시코, 76000
        • Cuidados oncologicos
    • Colorado
      • Denver, Colorado, 미국, 80220
        • Rocky Mountain Cancer Center - Denver
    • Connecticut
      • New Haven, Connecticut, 미국, 06520
        • Yale Cancer Center
    • Florida
      • St. Petersburg, Florida, 미국, 33705
        • SCRI Florida Cancer Specialists North
      • Tallahassee, Florida, 미국, 32308
        • SCRI Florida Cancer Specialists PAN
    • Minnesota
      • Saint Paul, Minnesota, 미국, 55102
        • US oncology research at Minnesota Oncology
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • SCRI Oncology Partners
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists (Fairfax) - USOR
      • Salem, Virginia, 미국, 24153
        • Onc & Hem Assoc SW Virginia
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, 브라질, 98700-000
        • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    • São Paulo
      • Barretos, São Paulo, 브라질, 14784-400
        • Hospital de Cancer de Barretos
      • Belgrade, 세르비아, 11000
        • Clinical Center of Serbia
      • Belgrade, 세르비아, 11080
        • University Hospital Medical Center Bezanijska kosa
      • Bern, 스위스, 3010
        • Inselspital Bern
      • Lausanne, 스위스, 1011
        • CHUV
      • Sankt Gallen, 스위스, 9000
        • HOCH Health Ostschweiz, Kantonsspital St. Gallen
      • Madrid, 스페인, 28041
        • Hospital 12 de Octubre
      • Madrid, 스페인, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid, 스페인, 41013
        • Hospital Universitario Virgen del Rocío
      • Málaga, 스페인, 29010
        • Hospital Regional Universitario de Malaga
      • Zaragoza, 스페인, 50009
        • Hosp Clinico Univ Lozano Blesa
    • Barcelona
      • Badalona, Barcelona, 스페인, 08916
        • Hospital Universitario Germans Trias i Pujol
      • Linz, 오스트리아, 4020
        • Ordensklinikum Linz Elisabethinen
      • Vienna, 오스트리아, 1140
        • Klinik Penzing
      • Vienna, 오스트리아, 1210
        • Krankenhaus Nord - Klinik Floridsdorf
      • Kryvyi Rih, 우크라이나, 50048
        • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
      • Uzhhorod, 우크라이나, 88000
        • Uzhgorod Nat. University Central Municip Hosp
    • Campania
      • Naples, Campania, 이탈리아, 80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    • Lazio
      • Rome, Lazio, 이탈리아, 00151
        • Azienda Ospedaliera San Camillo Forlanini
      • Rome, Lazio, 이탈리아, 00168
        • Policlinico Universitario "Agostino Gemelli"
    • Lombardy
      • Milan, Lombardy, 이탈리아, 20141
        • Irccs Istituto Europeo di Oncologia (IEO)
      • Monza, Lombardy, 이탈리아, 20900
        • Asst Di Monza
      • Rozzano, Lombardy, 이탈리아, 20089
        • Istituto Clinico Humanitas
    • Piedmont
      • Orbassano, Piedmont, 이탈리아, 10043
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    • Umbria
      • Perugia, Umbria, 이탈리아, 06156
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    • Veneto
      • Padova, Veneto, 이탈리아, 35128
        • IOV - Istituto Oncologico Veneto - IRCCS
      • Aichi, 일본, 464-8681
        • Aichi Cancer Center
      • Chiba, 일본, 277-8577
        • National Cancer Center Hospital East
      • Fukuoka, 일본, 812-8582
        • Kyushu University Hospital
      • Miyagi, 일본, 980-0873
        • Sendai Kousei Hospital
      • Niigata, 일본, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka, 일본, 589-8511
        • Kindai University Hospital
      • Osaka, 일본, 541-8567
        • Osaka International Cancer Institute
      • Saitama, 일본, 362-0806
        • Saitama Cancer Center
      • Sakaishi, 일본, 591-8555
        • NHO Kinki-Chuo Chest Medical Center
      • Shizuoka, 일본, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, 일본, 104-0045
        • National Cancer Center Hospital
      • Tokyo, 일본, 135-8550
        • The Cancer Institute Hospital of JFCR
      • Beijing, 중국, 100142
        • Beijing Cancer Hospital
      • Changchun, 중국, 130021
        • The First Hospital of Jilin University
      • Chengdu, 중국, 610041
        • West China Hospital, Sichuan University
      • Chongqing, 중국, 400030
        • Chongqing Cancer Hospital
      • Fuzhou, 중국, 350014
        • Fujian Cancer Hospital
      • Haikou, 중국, 570311
        • Hainan General Hospital
      • Hangzhou, 중국, 310016
        • Sir Run Run Shaw Hospital Zhejiang University
      • Harbin, 중국, 150081
        • Harbin Medical University Cancer Hospital
      • Jinan, 중국, 250013
        • Jinan Central Hospital
      • Meizhou, 중국, 514031
        • Meizhou People's Hospital
      • Nanchang, 중국, 330200
        • The 1st Affiliated Hospital of Nanchang Unversity
      • Nantong, 중국, 226361
        • Nantong Tumor Hospital
      • Shanghai, 중국, 200433
        • Shanghai Pulmonary Hospital
      • Shanghai, 중국, 200032
        • Zhongshan Hospital Fudan University
      • Shanghai, 중국, 200120
        • Fudan University Shanghai Cancer Center
      • Wuhan, 중국, 430022
        • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
      • Xi'an, 중국, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Zhejiang, 중국, 310022
        • Zhejiang Cancer Hospital
      • Bangkok, 태국, 10330
        • Chulalongkorn Hospital
      • Bangkok, 태국, 10400
        • Ramathibodi Hospital
      • Bangkok, 태국, 10700
        • Faculty of Med. Siriraj Hosp.
      • Songkhla, 태국, 90110
        • Songklanagarind Hospital
      • Adana, 터키 (Türkiye), 01120
        • Adana Baskent University Hospital
      • Ankara, 터키 (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Istanbul, 터키 (Türkiye), 34098
        • Istanbul University Cerrahpasa Faculty of Medicine
      • Izmir, 터키 (Türkiye), 35110
        • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
      • Kadiköy, 터키 (Türkiye), 34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital
      • Malatya, 터키 (Türkiye), 44280
        • Inonu University Medical Faculty of Medicine
      • Arequipa, 페루, 5154
        • Instituto Regional de Enfermedades Neoplásicas del Sur
      • Lima, 페루, 15038
        • Instituto Nacional de Enfermedades Neoplasicas
      • Lima, 페루, Lima 41
        • Clinica Internacional, Sede San Borja
      • San Isidro, 페루, Lima 27
        • Clinica Ricardo Palma
      • Gda?sk, 폴란드, 80-214
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn, 폴란드, 10-357
        • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
      • Poznan, 폴란드, 60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
      • Budapest, 헝가리, 1121
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Mátraháza, 헝가리, 3233
        • Matrai Gyogyintezet
      • Szolnok, 헝가리, 5004
        • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
    • Queensland
      • Woolloongabba, Queensland, 호주, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, 호주, 3084
        • Austin Hospital Olivia Newton John Cancer Centre
      • Melbourne, Victoria, 호주, 3000
        • Peter Maccallum Cancer Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Tiragolumab + Atezolizumab

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

다른 이름들:
  • 티센트릭

Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

다른 이름들:
  • MTIG7192A
위약 비교기: Placebo + Atezolizumab

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

다른 이름들:
  • 티센트릭

Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
기간: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
기간: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
기간: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
기간: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
기간: Up to 65.1 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 65.1 months
China Cohort: Number of Participants With AEs
기간: Up to 49.3 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
기간: Up to 65.1 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
기간: Up to 49.3 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 49.3 months

2차 결과 측정

결과 측정
측정값 설명
기간
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
기간: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
기간: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
기간: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
기간: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
기간: Up to approximately 54.6 months

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
기간: Up to 49.3 months

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
기간: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
기간: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
기간: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
기간: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
기간: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
기간: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
기간: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
기간: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
기간: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
기간: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
기간: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
기간: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
기간: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
기간: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
기간: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
기간: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
기간: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
기간: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
기간: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
기간: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
기간: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
기간: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Trial, Hoffmann-La Roche

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 3월 4일

기본 완료 (실제)

2025년 12월 30일

연구 완료 (실제)

2025년 12월 30일

연구 등록 날짜

최초 제출

2020년 3월 2일

QC 기준을 충족하는 최초 제출

2020년 3월 2일

처음 게시됨 (실제)

2020년 3월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • GO41717
  • 2019-002925-31 (EudraCT 번호)
  • 2019 (미국 NIH 보조금/계약)
  • 2022-502482-17-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다